• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LifeVantage Study Reveals Synergistic Effects Of Protandim Nrf2 Synergizer And TrueScience Liquid Collagen

    11/29/23 4:25:19 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email

    LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes, today announced that Company scientists have completed a study on the impact Protandim® Nrf2 Synergizer® and TrueScience® Liquid Collagen have on cellular health. The study results showed that when combined, the products work together to help cells accurately respond to stress levels and recover more quickly, supporting the body's immune function.

     

    "When cells are stressed they send out signals asking for help from the immune system," explained Lisa Barnes, Vice President of Research & Development. "However, even after the stressor is eliminated, it can be common for this signaling to continue, causing the immune system to waste precious energy trying to fix a problem that no longer exists. This unchecked cycle can lead to significant health concerns. The synergistic benefits of Protandim® Nrf2 Synergizer® and TrueScience® Liquid Collagen, help break this repetitive stress cycle by reducing unnecessary signaling, allowing cells to get back to their optimal function, which in this case is producing collagen."

    Barnes continued, "The study shows why people are seeing such incredible results with these two products. Together, they create a potent combination that drives cellular rebalance, helping to ensure cells are functioning properly. It's like sending your cells to a day at the spa, like the effect people are trying to achieve with ice plunges or cryotherapy. It's amazing how these two products work with your body to support its natural functions."

    "The results of this study are further proof that LifeVantage's unique emphasis on activation provides the optimal approach to health and wellness," said Steve Fife, President, and Chief Executive Officer. "Our products are clearly differentiated and have demonstrated their effectiveness in amplifying the body's natural processes to improve health starting at the cellular level. The science behind our products is one of the pillars of LifeVantage's competitive strength and supports the compelling business opportunity we offer for entrepreneurial minded individuals."

    Scientific Investigation Spurred by the Consumer Experience

    The study was designed after consumers provided significant anecdotal evidence about unexpected, positive results in gut health, joint health, along with improvements in overall energy and clarity. To understand why, Barnes and team devised a study in three parts: a dose-finding study, a gene expression study to verify dose timing and concentration, and a global gene expression study using RNA sequencing.

    Specifically, the study looked at the products' influence on fibroblasts. Found throughout the body, fibroblasts produce and organize components of the skin that act as the scaffold or support for the skin through proteins, including collagen, elastin, and laminin. Fibroblasts not only produce collagen and other proteins that make up the extracellular matrix for the skin, but they also perform the same function for other organs, such as the intestines, spleen, brain, lung, liver, kidney, and blood vessels.

    The gene expression study showed 13,195 genes distributed over 18,671 cellular pathways were influenced in the fibroblasts. Around 21% (2,786 genes) were significantly up, or downregulated either by Protandim Nrf2 Synergizer®, TrueScience® Liquid Collagen, or a combination of the two. Of the 2,786 genes measured, the combination of the two products synergistically influenced 2,439 genes (p<0.05), of which 418 genes (17%) were significantly up- (195 genes) or downregulated (223 genes).

    These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

    Get the next $LFVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid March 16, 2026 to all stockholders of record at the close of business on March 2, 2026. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products w

    2/4/26 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Planned Retirement of Steve Fife and CEO Succession Plan

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level, today announced that after nine years at LifeVantage, Steve Fife, President, Chief Executive Officer and a member of the Board of Directors (the "Board"), has decided to retire in April, 2026. Fife will continue in his role as President and Chief Executive Officer during the transition period to ensure business continuity through his retirement date. The Board is conducting an extensive executive search and anticipates announcing the new CEO in the coming months. "To ensure continuity and po

    2/4/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2025. Second Quarter Fiscal 2026 Summary*: Revenue was $48.9 million, a decrease of 27.8% from the prior year period. Revenue was up 2.9% sequentially from the first quarter.Revenue in the Americas decreased 32.6%, and revenue in Asia/Pacific & Europe decreased 2.1%.Net income per diluted share was $0.02, versus $0.19 per diluted share a year ago;Adjusted earnings per diluted share was $0.15, compared

    2/4/26 4:04:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dayton Judd bought $152,422 worth of shares (33,197 units at $4.59), increasing direct ownership by 70% to 80,359 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    3/2/26 6:44:28 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $20,651 worth of shares (3,955 units at $5.22), increasing direct ownership by 3% to 135,508 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    2/11/26 4:32:08 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Sales Officer Cunningham Kristen covered exercise/tax liability with 1,926 shares, decreasing direct ownership by 1% to 135,060 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    1/5/26 6:00:18 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dayton Judd bought $152,422 worth of shares (33,197 units at $4.59), increasing direct ownership by 70% to 80,359 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    3/2/26 6:44:28 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $20,651 worth of shares (3,955 units at $5.22), increasing direct ownership by 3% to 135,508 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    2/11/26 4:32:08 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $5,265 worth of shares (805 units at $6.54), increasing direct ownership by 0.62% to 131,553 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    12/17/25 4:23:51 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $LFVN
    SEC Filings

    View All

    Craig Hallum initiated coverage on Lifevantage with a new price target

    Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

    1/14/25 8:36:52 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Lifevantage with a new price target

    Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

    12/19/24 8:39:43 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Lifevantage Corporation

    S-3 - Lifevantage Corp (0000849146) (Filer)

    3/10/26 4:27:58 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lifevantage Corporation

    10-Q - Lifevantage Corp (0000849146) (Filer)

    2/4/26 4:05:35 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Lifevantage Corp (0000849146) (Filer)

    2/4/26 4:06:04 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Financials

    Live finance-specific insights

    View All

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid March 16, 2026 to all stockholders of record at the close of business on March 2, 2026. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products w

    2/4/26 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2025. Second Quarter Fiscal 2026 Summary*: Revenue was $48.9 million, a decrease of 27.8% from the prior year period. Revenue was up 2.9% sequentially from the first quarter.Revenue in the Americas decreased 32.6%, and revenue in Asia/Pacific & Europe decreased 2.1%.Net income per diluted share was $0.02, versus $0.19 per diluted share a year ago;Adjusted earnings per diluted share was $0.15, compared

    2/4/26 4:04:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on February 4, 2026

    SALT LAKE CITY, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its second quarter ended December 31, 2025, after the stock market closes on Wednesday, February 4, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hour

    1/21/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Leadership Updates

    Live Leadership Updates

    View All

    LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation

    SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the addition of Mike Edwards as Chief Technology Officer. Edwards brings more than 25 years of experience as an accomplished senior executive specializing in technology leadership and enterprise transformation. "Mike is a strategic leader with a strong track record of translating technological innovation into measurable business impact and we are delighted to have him join the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "His expertise in eCo

    1/7/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

    SALT LAKE CITY, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is proud to announce the addition of Todd Thompson as Chief Information and Innovation Officer. Todd brings decades of experience driving transformative technology solutions and business growth for prominent global organizations. "We are thrilled to welcome Todd to the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "Todd's exceptional track record in technology leadership and his forward-thinking approach will be pivotal as we continue along our growth path

    1/16/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    7/31/24 8:07:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:29:36 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:27:16 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care